Clinical Trial Update: A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating long-term safety of elexacaftor combination therapy in cystic fibrosis has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Elexacaftor combination therapy (elexacaftor/tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2023-07-28